ADMA vs. CPH.TO
ADMA (ADMA Biologics, Inc.) and CPH.TO (Cipher Pharmaceuticals Inc.) are both stocks. Both are in the Healthcare sector — ADMA in Biotechnology, CPH.TO in Drug Manufacturers - Specialty & Generic. Over the past 10 years, ADMA returned 1.08%/yr vs 7.91%/yr for CPH.TO. At a 0.06 correlation, their price movements are largely independent.
Performance
ADMA vs. CPH.TO - Performance Comparison
Loading charts...
Different Trading Currencies
ADMA is traded in USD, while CPH.TO is traded in CAD. To make them comparable, the CPH.TO values have been converted to USD using the latest available exchange rates.
Returns By Period
In the year-to-date period, ADMA achieves a -55.81% return, which is significantly lower than CPH.TO's 10.08% return. Over the past 10 years, ADMA has underperformed CPH.TO with an annualized return of 1.08%, while CPH.TO has yielded a comparatively higher 7.91% annualized return.
ADMA
- 1D
- 1.13%
- 1M
- -1.35%
- YTD
- -55.81%
- 6M
- -58.43%
- 1Y
- -60.89%
- 3Y*
- 28.26%
- 5Y*
- 34.37%
- 10Y*
- 1.08%
CPH.TO
- 1D
- -0.04%
- 1M
- -16.23%
- YTD
- 10.08%
- 6M
- 14.24%
- 1Y
- 24.86%
- 3Y*
- 62.35%
- 5Y*
- 56.53%
- 10Y*
- 7.91%
ADMA vs. CPH.TO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
ADMA ADMA Biologics, Inc. | -55.81% | 6.36% | 279.42% | 16.49% | 175.18% | -27.69% | -51.25% | 67.36% | -25.55% | -37.30% |
CPH.TO Cipher Pharmaceuticals Inc. | 10.08% | 10.20% | 138.31% | 47.79% | 104.02% | 90.42% | -36.49% | -8.51% | -67.81% | 7.26% |
Correlation
The correlation between ADMA and CPH.TO is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.06 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.14 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.09 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.06 |
Correlation (All Time) Calculated using the full available price history since Oct 17, 2013 | 0.06 |
Fundamentals
ADMA:
$1.93B
CPH.TO:
CA$435.58M
ADMA:
$0.68
CPH.TO:
CA$1.19
ADMA:
11.91
CPH.TO:
14.22
ADMA:
3.86
CPH.TO:
8.65
ADMA:
4.95
CPH.TO:
3.28
ADMA:
$509.86M
CPH.TO:
CA$50.92M
ADMA:
$312.42M
CPH.TO:
CA$37.95M
ADMA:
$218.74M
CPH.TO:
CA$25.12M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ADMA vs. CPH.TO — Risk / Return Rank
ADMA
CPH.TO
ADMA vs. CPH.TO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for ADMA Biologics, Inc. (ADMA) and Cipher Pharmaceuticals Inc. (CPH.TO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ADMA | CPH.TO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.71 | ||
| Sortino ratioReturn per unit of downside risk | -3.06 | ||
| Omega ratioGain probability vs. loss probability | 0.77 | 1.15 | -0.38 |
| Calmar ratioReturn relative to maximum drawdown | -0.94 | 1.03 | -1.97 |
| Martin ratioReturn relative to average drawdown | -1.81 | 2.22 | -4.03 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ADMA | CPH.TO | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -1.12 | 0.59 | -1.71 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.58 | 1.14 | -0.56 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.02 | 0.13 | -0.11 |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.01 | 0.07 | -0.08 |
Drawdowns
ADMA vs. CPH.TO - Drawdown Comparison
The maximum ADMA drawdown since its inception was -91.28%, smaller than the maximum CPH.TO drawdown of -98.29%. Use the drawdown chart below to compare losses from any high point for ADMA and CPH.TO.
Loading charts...
Drawdown Indicators
| ADMA | CPH.TO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.28% | -98.29% | +7.01% |
Max Drawdown (1Y)Largest decline over 1 year | -65.25% | -24.22% | -41.03% |
Max Drawdown (3Y)Largest decline over 3 years | -68.99% | -46.02% | -22.97% |
Max Drawdown (5Y)Largest decline over 5 years | -68.99% | -46.02% | -22.97% |
Max Drawdown (10Y)Largest decline over 10 years | -86.11% | -95.16% | +9.05% |
Current DrawdownCurrent decline from peak | -67.12% | -24.23% | -42.89% |
Average DrawdownAverage peak-to-trough decline | -53.05% | -65.74% | +12.69% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 33.62% | 11.22% | +22.40% |
Volatility
ADMA vs. CPH.TO - Volatility Comparison
The current volatility for ADMA Biologics, Inc. (ADMA) is 11.89%, while Cipher Pharmaceuticals Inc. (CPH.TO) has a volatility of 13.93%. This indicates that ADMA experiences smaller price fluctuations and is considered to be less risky than CPH.TO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ADMA | CPH.TO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 11.89% | 13.93% | -2.04% |
Volatility (6M)Calculated over the trailing 6-month period | 45.36% | 28.17% | +17.19% |
Volatility (1Y)Calculated over the trailing 1-year period | 54.73% | 42.14% | +12.59% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 59.46% | 49.98% | +9.48% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 69.05% | 61.43% | +7.62% |
Dividends
ADMA vs. CPH.TO - Dividend Comparison
Neither ADMA nor CPH.TO has paid dividends to shareholders.
Financials
ADMA vs. CPH.TO - Financials Comparison
This section allows you to compare key financial metrics between ADMA Biologics, Inc. and Cipher Pharmaceuticals Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ADMA vs. CPH.TO - Profitability Comparison
ADMA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a gross profit of 80.75M and revenue of 114.49M. Therefore, the gross margin over that period was 70.5%.
CPH.TO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Cipher Pharmaceuticals Inc. reported a gross profit of 8.35M and revenue of 12.30M. Therefore, the gross margin over that period was 67.9%.
ADMA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported an operating income of 58.27M and revenue of 114.49M, resulting in an operating margin of 50.9%.
CPH.TO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Cipher Pharmaceuticals Inc. reported an operating income of 5.50M and revenue of 12.30M, resulting in an operating margin of 44.7%.
ADMA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a net income of 45.33M and revenue of 114.49M, resulting in a net margin of 39.6%.
CPH.TO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Cipher Pharmaceuticals Inc. reported a net income of 6.06M and revenue of 12.30M, resulting in a net margin of 49.3%.
Frequently Asked Questions
ADMA and CPH.TO have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for ADMA and CPH.TO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer